Nosotti M, Dell'Amore A, Diso D, Oggionni T, Aliberti S
Department of Phato-physiology and Transplantation, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
Department of Cardiac-Thoracic and Vascular Diseases, Thoracic Surgery, University Hospital St. Orsola-Malpighi, Bologna, Italy.
Transplant Proc. 2017 May;49(4):702-706. doi: 10.1016/j.transproceed.2017.02.026.
Lung transplantation is a well-established treatment for selected patients with advanced chronic respiratory insufficiency. Recognizing those patients with end-stage lung disease who might benefit from lung transplantation is a crucial task. Considering the presence of inadequate evidence-based practice, international and national scientific societies provided consensus opinions regarding the appropriate timing of listing. The Study Group for Thoracic Organs Transplantation (branch of the Italian Society for Organs Transplantation) promoted and realized a Delphi conference among the Italian lung transplantation centers to provide guidance to clinical practice based on international recommendations. The experts from the nine Italian centers completed two rounds of standardized questionnaires (answer rate, 100%): 42 statements received a consensus ≥80%. The selected statements presented in this article are intended to assist Italian clinicians in selecting patients for lung transplantation.
肺移植是针对特定晚期慢性呼吸功能不全患者的一种成熟治疗方法。识别那些可能从肺移植中获益的终末期肺病患者是一项关键任务。鉴于缺乏循证实践,国际和国家科学协会就合适的列入名单时机提供了共识性意见。胸器官移植研究小组(意大利器官移植协会分会)在意大利肺移植中心之间推动并举办了一次德尔菲会议,以根据国际建议为临床实践提供指导。来自九个意大利中心的专家完成了两轮标准化问卷(回复率为100%):42条陈述获得了≥80%的共识。本文中列出的选定陈述旨在帮助意大利临床医生选择肺移植患者。